Findings

What do systematic reviews say?

2,510 questions · 2,653 findings · 194 reviews · Gynaecology and Fertility

Sort:Best matchNewestHighest certainty Download CSV

No studies found 531 · 20%GRADE not reported 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%

Mannitol vs placebo / no treatment

Adverse effects · women at high risk of OHSS

The review found no eligible studies for this question.

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Human albumin vs placebo or no treatment

Live birth · women at high risk of OHSS

The review found no eligible studies for this question.

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Human albumin vs placebo or no treatment

Pregnancy rate · women at high risk of OHSS

Human albumin probably leads to lower pregnancy rate compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.72 [0.55, 0.94]
7 studies · 1069 participants
Moderate

Human albumin vs placebo or no treatment

Adverse effects · women at high risk of OHSS

The review found no eligible studies for this question.

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HES vs placebo or no treatment

Moderate or severe OHSS · women at high risk of OHSS

It is very uncertain whether HES changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.27 [0.12, 0.59]
2 studies · 272 participants
Very low

HES vs placebo or no treatment

Live birth · women at high risk of OHSS

The review found no eligible studies for this question.

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HES vs placebo or no treatment

Pregnancy rate · women at high risk of OHSS

It is very uncertain whether HES changes pregnancy rate compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 1.2 [0.49, 2.93]
1 study · 168 participants
Very low

HES vs placebo or no treatment

Adverse effects · women at high risk of OHSS

The review found no eligible studies for this question.

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mannitol vs placebo / no treatment

Moderate or severe OHSS · women at high risk of OHSS

Mannitol may leads to lower moderate or severe OHSS compared with placebo / no treatment (low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.38 [0.22, 0.64]
1 study · 226 participants
Low

Oestrogen ring vs other regimens

Improvement in symptoms (participant‐assessed) (oestrogen ring vs oestrogen cream) · postmenopausal women with vaginal atrophy

Oestrogen ring showed no clear difference in improvement in symptoms (participant‐assessed) (oestrogen ring vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.33 [0.8, 2.19]
2 studies · 341 participants
Low

Oestrogen tablets vs other regimens

Endometrial thickness (mm) · postmenopausal women with vaginal atrophy

Oestrogen tablets showed no clear difference in endometrial thickness (oestrogen tablets vs oestrogen cream) compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.31 [0.06, 1.6]
2 studies · 151 participants
Low

Oestrogen tablets vs other regimens

Improvement in symptoms (clinician‐assessed) (oestrogen tablets vs oestrogen cream) · postmenopausal women with vaginal atrophy

Oestrogen tablets showed no clear difference in improvement in symptoms (clinician‐assessed) (oestrogen tablets vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.03 [0.7, 1.52]
3 studies · 528 participants
Low

Oestrogen tablets vs other regimens

Improvement in symptoms (clinician‐assessed) (oestrogen tablets vs placebo) · postmenopausal women with vaginal atrophy

Oestrogen tablets may leads to higher improvement in symptoms (clinician‐assessed) (oestrogen tablets vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 12.85 [10.39, 15.89]
4 studies · 2078 participants
Low

Oestrogen tablets vs other regimens

Adverse events (total adverse events) (oestrogen cream vs non‐hormonal lubricant gel) · postmenopausal women with vaginal atrophy

Oestrogen tablets showed no clear difference in adverse events (total adverse events) (oestrogen tablets vs placebo) compared with other regimens (moderate certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.27 [0.24, 6.69]
1 study · 309 participants
Moderate

Oestrogen cream vs other regimens

Improvement in symptoms (participant‐assessed) (oestrogen cream vs isoflavone gel) · postmenopausal women with vaginal atrophy

Oestrogen cream showed no clear difference in improvement in symptoms (participant‐assessed) (oestrogen cream vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 2.08 [0.08, 53.76]
1 study · 50 participants
Low

Oestrogen cream vs other regimens

Improvement in symptoms (participant‐assessed) oestrogen cream vs placebo) · postmenopausal women with vaginal atrophy

Oestrogen cream may leads to higher improvement in symptoms (participant‐assessed) oestrogen cream vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 4.1 [1.88, 8.93]
2 studies · 198 participants
Low

Oestrogen cream vs other regimens

Endometrial thickness not reported · postmenopausal women with vaginal atrophy

The review found no eligible studies for this question.

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen cream vs other regimens

Improvement in symptoms (clinician‐assessed) (oestrogen cream vs placebo) · postmenopausal women with vaginal atrophy

Oestrogen cream may leads to higher improvement in symptoms (clinician‐assessed) (oestrogen cream vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 3.29 [1.47, 7.36]
1 study · 153 participants
Low

Oestrogen cream vs other regimens

Adverse events (total adverse events) (oestrogen cream vs non‐hormonal lubricant gel) · postmenopausal women with vaginal atrophy

Oestrogen cream showed no clear difference in adverse events (total adverse events) (oestrogen cream vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 10.67 [0.54, 209.64]
1 study · 50 participants
Low

Oestrogen ring vs other regimens

Improvement in symptoms (participant‐assessed) (oestrogen ring vs oestrogen tablets) · postmenopausal women with vaginal atrophy

Oestrogen ring showed no clear difference in improvement in symptoms (participant‐assessed) (oestrogen ring vs… compared with other regimens (low certainty).

1 finding from 1 review

Local oestrogen for vaginal atrophy in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.78 [0.53, 1.15]
3 studies · 567 participants
Low